Evolus Appoints New CMO, Elects Director
Ticker: EOLS · Form: 8-K · Filed: Jul 1, 2024 · CIK: 1570562
Sentiment: neutral
Topics: executive-appointment, board-of-directors, personnel-change
Related Tickers: EVLS
TL;DR
Evolus shakes up leadership with a new CMO and board member.
AI Summary
Evolus, Inc. announced on July 1, 2024, the appointment of Dr. David J. Stark as Chief Medical Officer and the election of Ms. Sarah E. Gleason to its Board of Directors. Additionally, the company reported on compensatory arrangements for its named executive officers.
Why It Matters
These executive changes and board additions can signal shifts in leadership strategy and governance for Evolus, potentially impacting future product development and business direction.
Risk Assessment
Risk Level: low — The filing primarily concerns executive appointments and board changes, which are routine corporate governance events and do not inherently indicate significant financial or operational risks.
Key Players & Entities
- Evolus, Inc. (company) — Registrant
- Dr. David J. Stark (person) — Appointed Chief Medical Officer
- Ms. Sarah E. Gleason (person) — Elected to Board of Directors
- July 1, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer for Evolus, Inc.?
Dr. David J. Stark has been appointed as the new Chief Medical Officer for Evolus, Inc.
Who was elected to the Board of Directors of Evolus, Inc.?
Ms. Sarah E. Gleason was elected to the Board of Directors of Evolus, Inc.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is July 1, 2024.
What is the principal executive office address for Evolus, Inc.?
The principal executive office address is 520 Newport Center Drive, Suite 1200, Newport Beach, California 92660.
What is the Standard Industrial Classification code for Evolus, Inc.?
The Standard Industrial Classification code for Evolus, Inc. is 2834 (Pharmaceutical Preparations).
Filing Stats: 1,090 words · 4 min read · ~4 pages · Grade level 10.7 · Accepted 2024-07-01 16:39:08
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share EOLS The Nasdaq Stock Market
- $255,000 — its with a value equal to approximately $255,000. The stock units are scheduled to vest
- $50,000 — will also receive an annual retainer of $50,000 for service as a Board member and $7,50
- $7,500 — 0,000 for service as a Board member and $7,500 for services as a member of the Compens
Filing Documents
- eols-20240701.htm (8-K) — 35KB
- ex99171248k.htm (EX-99.1) — 18KB
- image_0.jpg (GRAPHIC) — 83KB
- 0001570562-24-000104.txt ( ) — 300KB
- eols-20240701.xsd (EX-101.SCH) — 2KB
- eols-20240701_lab.xml (EX-101.LAB) — 23KB
- eols-20240701_pre.xml (EX-101.PRE) — 13KB
- eols-20240701_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 1, 2024 , the Company issued a press release announcing the appointment of Mr. White to the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. As provided in General Instruction B.2 of Form 8-K, the information in this Item 7.01 (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 P ress Release of Evolus, Inc. dated July 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Evolus, Inc. Dated: July 1, 2024 /s/ David Moatazedi David Moatazedi President and Chief Executive Officer